ImpediMed receives FDA clearance

Company News

by Jessica Ellerm


ImpediMed Limited (ASX:IPD) has announced the US FDA has issued it with market clearance for its SOZOTM product.

SOZOTM is a connected platform that monitors fluid levels in heart failure patients, and is used under the direction of a physician in the clinic or home environments.

The clearance is another important regulatory milestone for the business, as it looks to provide a new model of care for cancer and heart failure patients.

Studies involving the use of SOZOTM technology have demonstrated detectable differences in whole-body extra-cellular fluid as low as 0.1 litres.

ImpediMed Limited (ASX:IPD) was trading around 5.91% higher this morning at $0.98

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.